Despite US marketing approval for the first histone deacetylase inhibitor, these prolific agents still have a lot to prove. Download PDF The approval by the US Food and Drug Administration (FDA) of ...

The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma ...

Fig 1. Mechanistic insights into kynurenine pathway modulation in renal cell carcinoma and therapeutic implications. This schematic illustrates the interplay between the kynurenine pathway, chromatin ...

DelveInsight’s 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...

A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the ...

The July approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) marks the third HDAC inhibitor to gain registration in the US and the first in almost five years—all for treating ...

As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...

Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase (HDAC) inhibitor HBI-8000 has succeeded in combination with Bristol Myers ...

Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation that is greater in patients with advanced disease. We asked whether there is a link between the severity of ...